Blar i AHUS - Diagnostikk og teknologi på tittel
Viser treff 21-26 av 26
-
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
(Oncoimmunology;7(11), Journal article; Peer reviewed, 2018-01-08)A high concentration of circulating vascular endothelial growth factor (VEGF) in cancer patients is associated with an aggressive tumor phenotype. Here, serum levels of 27 cytokines and blood cell counts were assessed in ... -
Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer
(Breast cancer research and treatment;172(2), Journal article; Peer reviewed, 2018-08-21)Purpose We have compared the mutational profiles of human breast cancer tumor samples belonging to all major subgroups with special emphasis on triple-negative breast cancer (TNBC). Our major goal was to identify specific ... -
A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America
(BMC cancer;17(1), Journal article; Peer reviewed, 2017-09-05)Background Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants ... -
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
(Genome medicine;10(1), Journal article; Peer reviewed, 2018-11-29)Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ... -
Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer
(Human Pathology;69, Journal article; Peer reviewed, 2017-11)Tumor-associated macrophages (TAM) resemble M2 macrophages, promote tumor invasion and show strong expression of CD163 in breast cancer. We here investigated the association between CD163-positive macrophages and vascular ... -
The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium
(Journal of Clinical Virology;108, Journal article; Peer reviewed, 2018-09-14)Background The VALidation of HPV GENoyping Tests (VALGENT) is an international initiative designed to validate HPV assays with genotyping capability. The VALGENT4 protocol differs from previous VALGENT installments as the ...